TY - JOUR
T1 - Fast-Proliferating adipose tissue mesenchymal-stromal-like cells for therapy
AU - Aguilar, Elisabet
AU - Bagó, Julio Rodriguez
AU - Soler-Botija, Carol
AU - Alieva, Maria
AU - Rigola, Maria Angeles
AU - Fuster, Carme
AU - Vila, Olaia F.
AU - Rubio, Nuria
AU - Blanco, Jeronimo
N1 - Publisher Copyright:
© 2014 Mary Ann Liebert, Inc.
PY - 2014/12/1
Y1 - 2014/12/1
N2 - Human mesenchymal stromal cells, whether from the bone marrow or adipose tissue (hASCs), are promising cell therapy agents. However, generation of abundant cells for therapy remains to be a challenge, due to the need of lengthy expansion and the risk of accumulating genomic defects during the process. We show that hASCs can be easily induced to a reversible fast-proliferating phenotype (FP-ASCs) that allows rapid generation of a clinically useful quantity of cells in <2 weeks of culture. Expanded FP-ASCs retain their finite expansion capacity and pluripotent properties. Despite the high proliferation rate, FP-ASCs show genomic stability by array-comparative genomic hybridization, and did not generate tumors when implanted for a long time in an SCID mouse model. Comparative analysis of gene expression patterns revealed a set of genes that can be used to characterize FP-ASCs and distinguish them from hASCs. As potential candidate therapeutic agents, FP-ASCs displayed high vasculogenic capacity in Matrigel assays. Moreover, application of hASCs and FP-ASCs in a fibrin scaffold over a myocardium infarct model in SCID mice showed that both cell types can differentiate to endothelial and myocardium lineages, although FP-ASCs were more potent angiogenesis inducers than hASCs, at promoting myocardium revascularization.
AB - Human mesenchymal stromal cells, whether from the bone marrow or adipose tissue (hASCs), are promising cell therapy agents. However, generation of abundant cells for therapy remains to be a challenge, due to the need of lengthy expansion and the risk of accumulating genomic defects during the process. We show that hASCs can be easily induced to a reversible fast-proliferating phenotype (FP-ASCs) that allows rapid generation of a clinically useful quantity of cells in <2 weeks of culture. Expanded FP-ASCs retain their finite expansion capacity and pluripotent properties. Despite the high proliferation rate, FP-ASCs show genomic stability by array-comparative genomic hybridization, and did not generate tumors when implanted for a long time in an SCID mouse model. Comparative analysis of gene expression patterns revealed a set of genes that can be used to characterize FP-ASCs and distinguish them from hASCs. As potential candidate therapeutic agents, FP-ASCs displayed high vasculogenic capacity in Matrigel assays. Moreover, application of hASCs and FP-ASCs in a fibrin scaffold over a myocardium infarct model in SCID mice showed that both cell types can differentiate to endothelial and myocardium lineages, although FP-ASCs were more potent angiogenesis inducers than hASCs, at promoting myocardium revascularization.
UR - http://www.scopus.com/inward/record.url?scp=84911362549&partnerID=8YFLogxK
U2 - 10.1089/scd.2014.0231
DO - 10.1089/scd.2014.0231
M3 - Article
C2 - 25019281
AN - SCOPUS:84911362549
SN - 1547-3287
VL - 23
SP - 2908
EP - 2920
JO - Stem Cells and Development
JF - Stem Cells and Development
IS - 23
ER -